IRCT20200406046963N2招募中3 期
Evaluation of the efficacy and safety of Adalimumab and methylprednisolone pulse therapy in treatment of Covid-19 patients with ARDS
Artesh University of Medical Sciences0 个研究点目标入组 40 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 90 years（—）
- 性别
- All
入选标准
- •Patient with moderate to severe Covid-19 admitted to ICU
- •PaO2/FiO2 Less than 300
- •LDH more than 450
- •Progression of disease severity and not responding to standard treatment
- •prediction of intubation for next 24 hours
排除标准
- •Uncontrolled diabetes mellitus
- •Active GI bleeding
- •history of corticosteroid hypersensitivity
- •sever electrolyte imbalances
- •Procalcitonin more than 0.5
- •active bacterial, viral ( HIV, Hepatitis) and fungal infection
研究者
相似试验
进行中（未招募）
不适用
Evaluation of the efficacy and safety of adalimumab (Humira) s.c. injections eow. in patients with adhesive capsulitis (frozen shoulder). - The TEST TrialEUCTR2006-005426-23-DKPierre Schydlowsky
已完成
不适用
The Study for Efficacy and Safety of Adalimumab for Crohn's Disease with Loss of Response to InfliximabCrohn's Disease patient as following 1)or 2) 1)the patient who treated with IFX infusion of interval every 4-6 weeks. 2)the patient who could not keep to treat with IFX due to side effect or ineffectiveness.JPRN-UMIN000005761Kenji Watanabe50
已完成
2 期
Evaluating the effects of Adalimumab in patients with acute respiratory distress syndrome caused by COVID-19IRCT20151227025726N23Shahid Beheshti University of Medical Sciences60
已完成
2 期
Adalimumab effectiveness in COVID-19COVID-19.C0VID-19U07.1IRCT20150303021315N22Tehran University of Medical Sciences40
进行中（未招募）
不适用
Review of Safety and Efficacy With Adalimumab in Patients With Active Ankylosing Spondylitis – An Open-Label Study to Evaluate the Response to Adalimumab in Patients Who Have Failed Standard Therapy or TNF-alpha Inhibitors. - RHAPSODYActive Ankylosing SpondylitisEUCTR2005-004826-21-NOAbbott Laboratories1,200